Abstract
Primary fibromyalgia syndrome (PFS) is an extra-articular rheumatic disease characterized by generalized muscle pain, skeletal muscle fatigue, and decreased pain threshold on palpation at specific points [4].
The relevance of the problem under consideration is determined by the medical, social and economic significance of the issue. To date, SPF appears to be the most common form of chronic myalgic syndromes [11]. So epidemiological data show that about 4% of the total population of the USA, Great Britain, and Sweden suffer from SPF. Abroad, the diagnosis of SPF is from 6% to 10% of general clinical practice and 15% of rheumatology. At the same time, 80-90% of persons with SPF are women, whose predominant age is 30-45 years, i.e. the most able-bodied [7].
Attention to SPF is due to the high prevalence of this pathology, the steadily progressive nature of the course, and the difficulties of drug therapy. Meanwhile, there are many unresolved issues in the SPF problem [2, 12]. Despite a wide range of clinical, electrophysiological, biochemical studies in this area, characteristic clinical and pathophysiological criteria have not been defined. According to most authors, physiotherapeutic and pharmacological agents currently used in the treatment of patients with SPF (antidepressants, muscle relaxants , NSAIDs) are effective in no more than half of the patients and do not provide stable improvement or remission [1, 6].